FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-02								

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

									_		_							_		
1. Name and Address of Reporting Person* <u>Riker Lauren Bullaro</u>					2. Issuer Name and Ticker or Trading Symbol Pacira BioSciences, Inc. [PCRX]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner							
	CIRA BIC	(First) SCIENCES, IN	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 12/23/2019]	below)	cer (give title ow) Vice President,		Other (s below) Finance	specify		
5 SYLVAN WAY, SUITE 300 (Street) PARSIPPANY NJ 07054					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)		(State)	(Zip)																	
		Та	ble I - No	n-Deriv	/ative	e Se	curit	ies Ac	qui	ired, C	Disp	osed c	of, or	Bene	ficial	y Owned	ł			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					2A. Deemed Execution Date if any (Month/Day/Yea		Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				5. Amou Securiti Benefici Owned	es ally Following	Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
										Code	v	Amount	(A	A) or D)	Price	Transac	Transaction(s) (Instr. 3 and 4)			,iiisu. 4)
Common Stock 12/23/3					3/2019	/2019		1	M ⁽¹⁾		1,000)	A	\$10.8	1 11	,464		D		
Common Stock 12/23/2					3/2019	2019 s ⁽¹⁾ 1,000 D		D	\$45.9	2 10	10,464		D							
			Table II -									sed of onverti				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deem Executior r) if any (Month/Da	Date,		Transaction Code (Instr.		ı of		6. Date Exercisal Expiration Date (Month/Day/Year			7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exer	e rcisable		xpiration ate	Title	or Nu of	ımber					
Stock Option (Right to Buy)	\$10.81	12/23/2019			M			1,000		(2)	00	6/05/2022	Comm		,000	\$0.00	27,820		D	

Explanation of Responses:

- 1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities
- 2. The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months.

Remarks:

/s/ Kristen Williams, Attorneyin-Fact

12/26/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.